Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Cilgavimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade |
---|---|
Source | DrugBank DB16393 |
Species | Humanized |
Expression system | Mammalian cells |
Molecular weight | 150kDa |
Purity | >85% |
Buffer | PBS pH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Cilgavimab,Cilgavimab, AZD1061,Covid Spike RBD,anti-Covid Spike RBD |
Reference | PX-TA1033 |
Note | For research use only. Not suitable for human use. |
Isotype | IgG1 |
Clonality | Monoclonal Antibody |
Cilgavimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Cilgavimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with Tixagevimab.
The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Cilgavimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.
Related products
Reviews
Il n’y a pas encore d’avis.